Drug Profile
Encochleated atovaquone - Matinas BioPharma
Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Aquarius Biotechnologies
- Developer Matinas BioPharma; National Institute of Allergy and Infectious Diseases
- Class Antiprotozoals; Naphthoquinones
- Mechanism of Action Electron transport complex I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pneumocystis pneumonia
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Pneumocystis pneumonia in USA (PO)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Pneumocystis pneumonia in USA (PO)
- 07 Jun 2018 Pharmacodynamics and pharmacokinetics data from preclinical studies in Pneumocystis pneumonia presented at the American Society for Microbiology's Microbe 2018 (ASMM-2018)